Categories
Politics

Texas abortion legislation in impact as Supreme Courtroom makes no transfer to dam it

Pedestrians walk past the US Supreme Court in Washington, DC, United States on Sunday, June 20, 2021.

Stefani Reynolds | Bloomberg | Getty Images

A Texas law banning most abortions went into effect Wednesday after the Supreme Court failed to respond to an urgency complaint to block its enforcement.

A group of abortion providers and advocates, including Planned Parenthood, had asked the Supreme Court to temporarily block enforcement of the law that would ban most abortions as early as six weeks of gestation.

The petitioners say the law would set Roe v. Wade, the landmark 1973 case that enshrined women’s right to abortion, essentially overturning it.

In response, a group of Texas officials, including Attorney General Ken Paxton, urged the Supreme Court to reject their opponents’ offer to thwart the law, calling the request “bold”.

SB 8 was enacted in May by Republican Governor Greg Abbott. It prohibits doctors from performing or having abortions after they “detect a fetal heartbeat in the unborn child” except in medical emergencies.

CNBC policy

Read more about CNBC’s political coverage:

The law prohibits state officials from enforcing these rules. Rather, it empowers anyone to bring civil actions against anyone who performs abortions or “helps or assists” them after a heartbeat is detected. These lawsuits can earn a minimum of $ 10,000 in “legal damages” per abortion.

If it went into effect, the bill would “immediately and catastrophically restrict access to abortion in Texas, ban the care of at least 85% of abortion patients in Texas,” and likely force many providers to shut down, the urgency motion filed Monday said .

This motion was filed directly with Conservative Judge Samuel Alito, who is handling inquiries from the Lone Star State. It was filed days after a lower appeals court refused to block implementation of the law.

Alito had asked respondents to respond to the appeal by 5 p.m. ET Tuesday.

“In less than two days, Texan politicians will have effectively overthrown Roe v. Wade,” said Nancy Northup, CEO of the Center for Reproductive Rights, whose organization helped the Supreme Court filing the motion, in a statement Monday.

The Supreme Court, which has a conservative majority of 6: 3 after the administration of former President Donald Trump, is already supposed to hear arguments in a potentially decisive abortion case from Mississippi. This state has urged judges to reconsider existing precedents preventing states from banning abortions that occur before the fetus is viable.

This is the evolution of news. Please check again for updates.

– CNBC’s Christine Wang contributed to this report.

Categories
Health

A Vaccine Aspect Impact Leaves Ladies Questioning: Why Isn’t the Capsule Safer?

Last month, as the Food and Drug Administration paused use of Johnson & Johnson’s Covid-19 vaccine to evaluate the risk of blood clots in women under 50, many scientists noted that clots associated with birth control pills were much more common.

The comparison was intended to reassure women of the vaccine’s safety. Instead, it has stoked anger in some quarters — not about the pause, but about the fact that most contraceptives available to women are hundreds of times riskier, and yet safer alternatives are not in sight.

The clots linked to the vaccine were a dangerous type in the brain, while birth control pills increase the chances of a blood clot in the leg or lung — a point quickly noted by many experts. But the distinction made little difference to some women.

“Where was everyone’s concern for blood clots when we started putting 14-year-old girls on the pill,” one woman wrote on Twitter.

Another said, “If birth control was made for men it’d taste like bacon and be free.”

Some women heard, on social media and elsewhere, that they should not complain because they had chosen to take birth control knowing the risks involved. “That just made me double down,” said Mia Brett, an expert in legal history focused on race and sexuality. “This is such a common response to women’s health care — that we point out something and it’s dismissed.”

The torrent of fury online was familiar to experts in women’s health. “They should be angry — women’s health just does not get equal attention,” said Dr. Eve Feinberg, a reproductive endocrinologist and infertility specialist at Northwestern University. “There’s a huge sex bias in all of medicine.”

Dr. Feinberg and many of the women online acknowledge that contraceptives have given women control over their fertility, and the benefits far exceed the harms. Rebecca Fishbein, a 31-year-old culture writer, started tweeting about the inadequacy of birth control pills almost immediately after the announcement of the pause.

Still, “birth control is an incredible invention, thank God we have it,” she said last month in an interview. “I’ll fight anyone who tried to take it away.”

Contraceptives have also improved over the years, with intrauterine devices and oral options that offer an ultralow dose of estrogen. “Over all, it’s incredibly safe,” Dr. Feinberg said. “Everything that we do has risks.”

But Dr. Feinberg said it was crucial for health care providers to discuss the risks with their patients and coach them on worrisome symptoms — a conversation many women said they had never had.

Kelly Tyrrell, a communications professional in Madison, Wis., was 37 when doctors discovered potentially fatal blood clots in her lungs.

Ms. Tyrrell is an endurance athlete — wiry, strong and not prone to anxiety. In early 2019, she began waking up with a pain in her left calf. After one particularly bad morning, an urgent care visit revealed that she had high blood levels of “D dimer,” a protein fragment that indicates the presence of clots.

She had been taking birth control pills for 25 years, but none of the doctors made a connection. Instead, they said that given her age, fitness and the lack of other risk factors, her symptoms were unlikely to be from a blood clot. They sent her home with instructions to do stretches for her calf muscle.

When she felt a tightness in her chest while running in Hawaii after her grandmother’s funeral, doctors said the cause was probably stress and anxiety. In July 2019, she finished a 100K race in Colorado and assumed her aching lungs and purple lips were the result of running for 19 hours at a high altitude.

But she knew something was seriously wrong on the morning of Oct. 24, 2019, when she became short of breath after walking up a short flight of stairs.

This time, after ruling out heart problems, doctors scanned her lungs and discovered multiple clots. One had cut off blood flow to a portion of her right lung.

“I instantly burst into tears,” Ms. Tyrrell recalled. The doctors put her on a course of blood thinners — and told her never to touch estrogen again. Ms. Tyrrell switched to a copper IUD. Over time, she added, the incident had escalated into a sharp rage that was renewed by the Johnson & Johnson news.

“Part of my anger was that a medication that I took to control my fertility ended up threatening my mortality,” she said. “I’m angry that I hadn’t been counseled better about that risk, or even what to look for.”

Emily Farris, 36, was prescribed oral contraceptives at age 18 to help with migraines. In all of the conversations she has had with her many doctors over the years, “never once was blood clots brought up,” she said in an interview.

On Twitter, some critics pointed out that the inserts with birth control packs clearly describe the blood clot risk. “My response is a bit incredulous to that,” said Dr. Farris, a political scientist at Texas Christian University in Fort Worth.

The inserts for most medications have a long list of possible side effects, placing “a high burden for folks to try to sort through medical research, to sort through what probability and statistics mean,” she said.

Even with a Ph.D.-level education, “I can’t assess those risks,” Dr. Farris added. “I think most Americans need someone to translate what the legalese kind of pamphlet is into real terms.”

For Ms. Tyrrell, that elucidation came much too late. Her lungs have not felt the same since her diagnosis, but she is not sure whether that is because of lingering damage from a previous blood clot, new clots that she should be worried about or simply her age, she said, adding, “It’s never not on my mind anymore.”

Categories
Health

A Covid Vaccine Facet Impact, Enlarged Lymph Nodes, Can Be Mistaken for Most cancers

Coronavirus vaccinations can cause enlarged lymph nodes in the armpit or near the collarbone, which may be mistaken for a sign of cancer.

As vaccines roll out across the country, doctors are seeing more and more of these swollen lumps in recently vaccinated people, and medical journals have started publishing reports aimed at reducing anxiety and helping patients avoid unnecessary testing for a harmless condition that will go away a couple of weeks.

The swelling is a normal immune system response to the vaccine and occurs on the same side as the arm the shot was fired on. It can also occur after other vaccinations, including those for the flu and human papillomavirus (HPV). Patients may or may not notice it. However, the enlarged lymph nodes appear as white spots on mammograms and breast scans and are similar to pictures that may indicate the spread of cancer through a tumor in the breast or elsewhere in the body.

“I make special efforts to inform all patients who are being monitored after successful previous cancer treatment,” said Dr. Constance D. Lehman, author of two magazine articles on the problem and director of breast imaging at Massachusetts General Hospital. “I can’t imagine the fear of getting the scan and hearing. ‘We found a lump that is big. We don’t believe it is cancer, but we can’t tell, or worse, we believe it could be cancer. “

The armpit swelling was a recognized side effect in the large studies of the Moderna and Pfizer-BioNTech vaccines. In Moderna’s study, 11.6 percent of patients reported swollen lymph nodes after the first dose and 16 percent after the second dose. Pfizer-BioNTech appeared to have a lower incidence, with 0.3 percent of patients reporting it. However, these numbers only reflect what patients and their doctors have noticed, and radiologists say the real rate is likely higher and that imaging such as mammograms, MRIs, or CT scans are likely to have many more cases.

The condition was not listed among the reported side effects in a Food and Drug Administration information document about the Johnson & Johnson Covid vaccine. On Saturday, the agency approved the company’s emergency vaccine.

Dr. Lehman said it was important for imaging centers to ask patients if they received Covid vaccinations and to record the date of the shot and the arm it was placed in.

Your clinic includes this notice in a letter to patients whose screening reveals swelling but no other abnormalities: “The lymph nodes in your armpit area that we see on your mammogram are on the page where you got your last Covid-19 vaccine got bigger. Enlarged lymph nodes are common after the Covid-19 vaccine and are your body’s normal response to the vaccine. However, if you feel a lump in your armpit that lasts more than six weeks after your vaccination, you should tell your doctor. “

One way to avoid the problem is to postpone routine mammograms and other imaging tests for at least six weeks after the last dose of vaccine. This comes from a panel of experts article in Radiology magazine published on Wednesday.

Updated

March 1, 2021, 3:41 p.m. ET

A professional group, the Society of Breast Imaging, offers similar advice: “If possible and if care is not unduly delayed, you should schedule screening exams before the first dose of Covid-19 vaccine or 4-6 weeks after the second dose.” a Covid-19 vaccination. “

However, the panel of experts also warned that non-routine imaging, which is needed to treat a disease or other symptoms that could suggest cancer, should not be delayed. Immunization should also not take place.

People with cancer are generally recommended to get vaccinated against the coronavirus, especially because they are at a higher risk of dying from Covid than the general population. However, some cancer treatments can affect the body’s ability to fully respond to the vaccine, and the American Cancer Society advises patients to consult with their oncologists about vaccinations.

Recently vaccinated people who have cancer and develop enlarged lymph nodes may need additional tests, including a biopsy of the nodes, said Dr. Lehman.

She described a patient with a newly diagnosed breast tumor who had swollen lymph nodes on the same side and who had recently received a Covid shot in the arm on that side.

A biopsy was performed, an important step to determine if there were any malignant cells in the nodes, which would then help determine a course of treatment. It was negative for cancer. The vaccine most likely caused the swelling.

In another case, a woman who previously had cancer of the right breast had a routine mammogram that showed an enlarged lymph node in her left armpit and no other abnormality. She recently had a Covid vaccination on her left arm. Doctors found that no further testing would be needed if the swollen lumps did not last more than six weeks.

A man with a history of bone cancer did a chest CT scan as part of a follow-up exam found swollen lymph nodes in one armpit – on the side where he had recently received a Covid shot. Nothing else was wrong and no further testing was required. The same decision was made for similar findings in a recently vaccinated man who had a chest CT scan to screen for lung cancer and in a woman with a history of melanoma.

For patients undergoing cancer treatment in one breast, the Covid shot should be given in the arm on the other side, said Dr. Lehman. The vaccine can also be injected into the thigh to avoid problems with lymph node swelling.

“This could really affect a lot of people if we don’t get vaccination status straight away in imaging centers,” said Dr. Lehman. “I also want cancer patients to know that they can get the vaccine on the opposite side or even on the leg to avoid confusion.”

Categories
Health

Which Covid Vaccine Ought to You Get? Specialists Weigh the Impact Towards Extreme Illness

At first glance, the results reported on Friday of the long-awaited study of Johnson & Johnson’s coronavirus vaccine may have been disappointing. Overall effectiveness – the ability to prevent moderate and severe illnesses – was reported at 72 percent in the United States, 66 percent in Latin American countries, and 57 percent in South Africa.

These numbers are well below the high bar set by Pfizer-BioNTech and Moderna, the first two emergency vaccines approved in the United States, which had an overall effectiveness of 94 to 95 percent.

Dr. Anthony S. Fauci, the nation’s leading infectious disease expert and now President Biden’s leading medical advisor on the coronavirus pandemic, acknowledged the remarkable difference at a briefing Friday.

“If you woke up and say, ‘Well, go to the left door and you get 94 or 95 percent, go to the right door and you get 72 percent. ‘Which door do you want to go to? ”He asked.

Dr. However, Fauci said the most important measure is the ability to prevent serious illness, which means keeping people out of the hospital and preventing deaths. For Johnson & Johnson, that result was 85 percent in all of the countries it was tested in, including South Africa, where a rapidly spreading variant of the virus had shown some ability to evade vaccines.

More important than preventing “some pain and a sore throat,” said Dr. Fauci, is the defense against serious illnesses, especially in people with underlying diseases and in older adults who are more likely to become seriously ill and die of Covid. 19th

“If you can prevent serious illness in a high percentage of people, it will soothe the stress of human suffering and death in this epidemic that we are seeing it right now,” said Dr. Fauci, “As we know, over the past few weeks our healthcare system has been burdened by the number of people requiring hospitalization and intensive care.”

Dr. Francis Collins, director of the National Institutes of Health, compared the ability to prevent serious illness to the effects of flu vaccinations, which may not always prevent influenza completely, but make it less severe.

“The same seems to be true here, in circumstances where this variant clearly makes it a little harder to get the most forceful response you want,” said Dr. Collins. “But it still looks very good for serious illnesses.”

The Moderna vaccine also showed high 100 percent effectiveness against serious illnesses. The Pfizer BioNTech appeared to be too, but the total number of severe cases in the study was too few to be certain.

However, the researchers caution that trying to compare effectiveness between new and previous studies can be misleading because the virus is developing quickly and the studies have to some extent examined different pathogens.

“You have to realize that Pfizer and Moderna had an advantage,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University, in an interview. “They did their clinical studies before the variant strains became very clear. Johnson & Johnson not only tested their vaccine against the standard strain, but they also had the variants. “

The best way to stop the spread of mutants and prevent new ones from emerging is to vaccinate as many people as you can as soon as possible, says Dr. Fauci and other researchers. Viruses can’t mutate if they can’t replicate, and they can’t replicate if they can’t get into cells. Keeping them away from people by immunizing them can kill the process.

In addition to the Pfizer BioNTech and Moderna vaccines already in use in the US, three more may soon be available: those made by Novavax, Johnson & Johnson and AstraZeneca. AstraZeneca’s vaccine has already been approved in the UK and other countries.

Globally, the Johnson & Johnson vaccine is expected to play an important role, especially in low- and middle-income countries, as it works after just one shot, is relatively inexpensive, and is easier to store and distribute than Pfizer-BioNTech’s manufactured vaccines and Moderna, as it does not share their strict requirements for freezing and chilling.

People waiting to be vaccinated may wonder if they will be able to choose vaccines and if they should hold out and wait until the one that looks best to them becomes available.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over the age of 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This could be the case for people who are charged a doctor’s visit fee with their vaccine or for Americans who have certain types of health insurance that are not covered by the new regulations. If you received your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine at a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

Dr. Paul Offit, a vaccines expert at Philadelphia Children’s Hospital, told CNN that Pfizer-BioNTech and Moderna vaccines would be his first choice when they were abundant because of their higher overall effectiveness.

But right now there aren’t enough of these vaccines.

If he couldn’t get the Pfizer BioNTech vaccine or the Moderna vaccine, he would do the Johnson & Johnson shot, said Dr. Offit – as long as the data the company will submit to the Food and Drug Administration looks as good as the company reported on Friday.

He said Johnson & Johnson’s Serious Disease Reduction Report was a strong selling point.

“That’s what you want,” said Dr. Offit. “You want to stay out of the hospital and out of the morgue.”

He noted that the company was also investigating a two-shot regimen that could increase its effectiveness.

People taking the Johnson & Johnson vaccine should be able to safely get a Pfizer BioNTech or Moderna vaccine later if a booster shot is needed, he said.

Dr. Schaffner said he had just attended a meeting with other public health experts and they asked each other what they would say to their spouses or partners if they could get the Johnson & Johnson vaccine tomorrow or had to wait three weeks Pfizer- BioNTech’s or Moderna’s.

“We all said, ‘Get it tomorrow,” said Dr. Schaffner. “The virus is bad. You risk another three weeks of exposure instead of receiving protection tomorrow.”

He said the 85 percent effectiveness of Johnson & Johnson against serious illnesses is a little less than that reported by Moderna and Pfizer-BioNTech, “but it’s still damn high.”

It is not yet known whether it is safe to take a different type of vaccine every now and then, said Dr. Schaffner, adding, “We haven’t investigated this.”

Categories
Business

One Vaccine Aspect Impact: World Financial Inequality

LONDON – The end of the pandemic is finally in sight. This also applies to the rescue from the most traumatic global economic catastrophe since the Great Depression. With the entry of Covid vaccines into the bloodstream, recovery has become a reality.

However, the benefits will not be evenly distributed by far. Wealthy nations in Europe and North America have secured the bulk of limited vaccine supplies and positioned themselves for greatly improved economic fortunes. Developing countries – home to most of the people – need to secure their own doses.

The unilateral distribution of vaccines seems to be worsening a defining economic reality: the world that emerges from this terrible chapter in history will be more unequal than ever. Poor countries continue to be ravaged by the pandemic, forcing them to divert meager resources already strained by growing debt to lenders in the US, Europe and China.

The global economy has long been divided by profound differences in wealth, education, and access to vital elements such as clean water, electricity, and the internet. The pandemic has trained the death and livelihood destruction of ethnic minority groups, women and lower-income households. The ending is likely to add another divide that could shape economic life for years, separating countries with access to vaccines from countries without vaccines.

“It is clear that developing countries, and poorer developing countries in particular, will be excluded for some time,” said Richard Kozul-Wright, Director of Globalization and Development Strategies at the United Nations Conference on Trade and Development in Geneva. “Despite the understanding that vaccines must be considered a global good, their supply remains largely under the control of large pharmaceutical companies in the advanced economies.”

International aid agencies, philanthropists and wealthy nations have come together on a pledge to ensure that all countries have the tools necessary to fight the pandemic, such as protective equipment for medical teams, as well as tests, therapeutics and vaccines. But they failed to back their pledges with enough money.

Leading initiative, the Act Accelerator Partnership – a World Health Organization company and the Bill and Melinda Gates Foundation – has secured less than $ 5 billion out of $ 38 billion.

A group of developing countries, led by India and South Africa, tried to increase the supply of vaccines by making their own vaccines, ideally in collaboration with the pharmaceutical companies that made the leading versions. To ensure leverage, the group has suggested that the World Trade Organization abandon traditional intellectual property protections to allow poor countries to produce affordable versions of the vaccines.

The W.TO. works by consensus. The proposal has been blocked by the United States, Britain and the European Union, where pharmaceutical companies exercise political influence. The industry argues that patent protection and the benefits it brings are a prerequisite for the innovation that creates life-saving drugs.

Proponents of patent suspension note that many blockbuster drugs are brought to market through government funded research, arguing that doing so is a need to put the social good at the center of politics.

“The question really is,” is this a time to profit? “Said Mustaqeem De Gama, Councilor for the South African Mission to the WTO in Geneva.” We have seen governments shut down economies and curtail freedoms, but intellectual property is seen as so sacrosanct that it cannot be touched. “

In the rich countries that have secured access to vaccines, the public health emergency is currently solving the economic disaster. The restrictions that closed businesses could be lifted and bring significant economic benefits as early as March or April.

At the moment the picture is bleak. The United States, the world’s largest economy, has suffered the equivalent of September 11 death daily, which makes a return to normal seem far away. Large economies like the UK, France and Germany are locked again as the virus continues to gain momentum.

After a decline of 4.2 percent this year, the world economy is expected to grow by 5.2 percent next year, according to Oxford Economics. That forecast assumes annual growth of 4.2 percent in the US and an expansion of 7.8 percent in China, the second largest economy in the world where government measures have controlled the virus.

According to IHS Markit, given the spread of the virus, Europe will lag behind as the continent’s economy does not return to its pre-crisis size for two years. An agreement signed Thursday between the UK and the European Union that will keep much of their trade ties in place after Brexit has allayed worst fears of a slowdown in regional trade.

According to Oxford Economics, the long-term economic damage from the pandemic in so-called emerging countries will be twice as high as in wealthy countries by 2025.

Such predictions are notoriously inaccurate. A year ago, no one predicted a catastrophic pandemic. The variables that the global economy is currently facing are particularly large.

The manufacture of vaccines is fraught with challenges that could limit supply while their endurance and effectiveness are not fully understood. The economic recovery will be shaped by psychological issues. After the deepest shock in memory, how will societies exercise their freedom of movement once the virus is tamed? Will lock-exempt people come together in cinemas and airplanes?

Persistent aversion to the human community is likely to limit growth in the leisure and hospitality industries, which are major employers.

The pandemic has accelerated the advancement of e-commerce, leaving traditional brick and mortar retailers in a particularly vulnerable state. If a persistent sense of fear leads shoppers to avoid shopping malls, it could limit employment growth. Online retailers like Amazon have aggressively embraced automation, which means that increasing business doesn’t necessarily translate into quality jobs.

Many economists believe that if the vaccines relieve anxiety, people will head for out-of-bounds experiences, crowded restaurants, sporting events, and vacation destinations. Households saved because they canceled their vacation and talked at home.

“If people’s moods are relaxed and some of the restrictions lifted, there could be a loss of spending,” said Ben May, a global economist with Oxford Economics in London. “Much of this will be about the speed and degree to which people return to more normal behaviors. It’s very hard to know. “

But many developing countries will effectively live on another planet.

The United States has made claims for up to 1.5 billion doses of vaccine, while the European Union has blocked nearly two billion doses – enough to vaccinate all of its citizens and a few more. Many poor countries could wait until 2024 to fully vaccinate their populations.

High debt burdens limit the ability of many poor countries to pay for vaccines. Private creditors have refused to participate in a debt suspension initiative advocated by the group of 20.

The promised aid from the World Bank and the International Monetary Fund has turned out to be disappointing. At the IMF, the Trump administration has spoken out against the expansion of so-called special drawing rights – the institution’s basic currency – and has withdrawn additional resources from poor countries.

“The international response to the pandemic has been essentially pathetic,” said Kozul-Wright of the UN Trade Organization. “We are concerned that we will see the same thing again when the vaccines are distributed.”

One element of the Act Accelerator partnership, known as Covax, is supposed to allow poor countries to buy vaccines at affordable prices, but it collides with the reality that production is both limited and controlled by for-profit companies that face shareholders are responsible.

“Most of the people in the world live in countries where they rely on Covax for access to vaccines,” said Mark Eccleston-Turner, an international law and infectious disease expert at Keele University in England. “This is an extraordinary market failure. Access to vaccines is not needs-based. It is solvency based and Covax does not address this issue. “

On December 18, Covax officials announced a deal with pharmaceutical companies aimed at providing nearly two billion doses of vaccines to low- and middle-income countries. The agreement, which focuses on vaccine candidates that have not yet been approved, would provide enough doses to vaccinate a fifth of the population in 190 participating countries by the end of next year.

India is home to pharmaceutical manufacturers who make vaccines for multinational companies like AstraZeneca. However, according to TS Lombard, an investment research firm based in London, the population is unlikely to be fully vaccinated before 2024. The economy is likely to remain fragile.

Even if masses of people in poor countries do not have access to vaccines, their economies are likely to take advantage of the normalization of richer nations. In a world of inequality, growth can coincide with inequality.

If consumer power resumes in North America, Europe, and East Asia, it will boost demand for raw materials, rejuvenate copper mines in Chile and Zambia, and boost exports of soybeans harvested in Brazil and Argentina. Tourists will eventually return to Thailand, Indonesia, and Turkey.

However, some argue that the ravages of the pandemic in poor countries, largely unchecked by vaccines, could limit economic fate worldwide. If the poorest countries don’t get vaccines, the world economy will lose $ 153 billion in annual output, according to a recent study by the RAND Corporation.

“You need to vaccinate health care workers around the world so you can reopen global markets,” said Clare Wenham, a health policy expert at the London School of Economics. “If every country in the world can say, ‘We know that all of our vulnerable people are vaccinated,’ we can get back to the global capitalist trading system much faster.”

Categories
Business

Milwaukee Bucks credit score ‘Giannis impact’ for uptick in enterprise

Giannis Antetokounmpo of the Milwaukee Bucks

Gregory Shamus | Getty Images

The Milwaukee Bucks credit Giannis Antetokounmpo with a surge in goods sales.

Moments after the incumbent National Basketball Association MVP posted on his Instagram account that he would be on the team until at least 2026, the “Giannis Effect” accelerated, particularly with regard to a critical good.

In the first 18 hours since Antetokounmpo’s move, the Bucks said they saw 1.3 million video views on social media channels and a 186% increase in online goods orders. The team added that 85% of its retail sales came after reporting the move on Twitter, and 55% of the items purchased were Antetokounmpo goods, according to Bucks.

Perhaps the most significant impact on team business due to Antetokounmpo’s decision was the negotiating table around the jersey patch.

“The phone calls started two-way,” said Matt Pazaras, Bucks chief business development and strategy officer. In an interview with CNBC Thursday, Pazaras said the Bucks deal “generated a lot of activity”. The team patch deal with Harley-Davidson expired after last season.

In November, Peter Feigin, president of Bucks and the team’s arena, Fiserv Forum, told CNBC that the team was on the verge of attracting a new sponsor for the patch, which they expect to do this month.

After Antetokounmpo agreed with the Bucks on Tuesday for a five-year extension of $ 225 million that marked the NBA’s Supermax deal, Pazaras said demand for sponsors for the new patch had increased and the team returned Obtain sponsorship offers.

Prior to the renewal, Pazaras said potential sponsors were on “wait and see” mode to sign a long-term patch contract with the team, fearing the value would not be there if Antetokounmpo competed for a free agency in 2021.

“Our message was the same as (General Manager) Jon Horst brought out. ‘We’re feeling good with Giannis and it would be a good time to get the deal because there would be a lot more interest after that,” said Pazaras. “I got the feeling people would rather pay the premium knowing Giannis is locked up than take the chance with us if he doesn’t sign again.”

The NBA generated approximately $ 150 million in additional revenue from its patch program, which was introduced for the 2017-18 season.

Pazaras didn’t discuss details of the value of the Bucks patch, but veteran marketing manager Tony Ponturo estimated that some patch assets represent a “$ 5 million opportunity right now” and that it will be a buyer’s market if Companies tackling the Covid-19 pandemic.

But the Bucks, owned by Avenue Capital CEO and chairman Marc Lasry, will beat that price as Antetokounmpo is tied to itself for the long term.

LeBron James from Team LeBron and Giannis Antetokounmpo from Team Giannis pose for a picture after the 2019 NBA All-Star Game

Nathaniel S. Butler

International star power

Sponsors sometimes pay a lot of money to get their logos on a jersey.

The Stephen Curry-led Golden State Warriors have an approximately $ 20 million annual agreement with Japanese e-commerce company Rakuten.

The Los Angeles Lakers’ estimated patch of $ 12-14 million a year is likely to be on the agenda with LeBron James, and the Brooklyn Nets should with the return of more weight around their patch (most recently valued at $ 8 million per year) have Kevin Durant.

The Bucks are likely to charge $ 10 to 15 million, with Antetokounmpo safe now. The team is again represented in the NBA line-up on Christmas Day this year and plays the Warriors. The national TV trend is expected to continue with the international star.

The Bucks hired Chicago-based research and evaluation firm Navigate, which tracks the effectiveness of its patch impressions, to provide data to sponsors. According to Pazaras, partners are aiming for national viewership and brand exposure on social media accounts outside of team channels. The postseason generates even more income.

“That’s one of the most important metrics that we’re showing, the value it has of going further in the playoffs,” said Pazaras of the global reach that the NBA playoffs offer.

The Bucks will likely structure their new deal to include bonuses that companies pay for post-season presence. Calling it a “round media rating”, Pazaras said it had “become common to have playoff bonuses for every round in the deal”. More and more NBA teams are entering into agreements in which sponsors pay more for the patch as the teams advance.

Pazaras said the team has about 30 companies watching the Bucks patch and five companies are in “serious talks.”

The patch deal could include signage options in the arena as well, but the NBA team presidents are relying on the newly installed international marketing to add value as well.

Teams can now designate up to three corporate partners who can freely use their intellectual property outside of the US and Canada. Again, the “Giannis Effect” will support the team as its global appeal is one of the best in the league.

“It has grown so big that it’s all of Europe and especially Asia,” said Pazaras. “The Philippines is a huge market for us. Giannis has become a global icon. He has grown so big.

“Giannis always brags that he was the best salesman in Greece,” added Pazaras. “And now we’re trying to make him the bucks best seller. He helped us on Tuesday. I can tell you that.”